MP
ICU icon

Mangrove Partners’s SeaStar Medical ICU Stock Holding History

Mangrove Partners’s Portfolio ICU Stock Details ICU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,200
Closed -$2.97M – 365
2021
Q2 		$2.97M Hold
1,200
– – 0.31% 69
2021
Q1 		$2.94M Buy
+1,200
New +$2.94M 0.3% 87

Other funds holding ICU

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Mangrove Partners's ICU Position: Q3 2021 in Review

Mangrove Partners sold out of SeaStar Medical (ICU) in Q3 2021, closing a stake of 1,200 shares — an estimated $2.97M sold.

Mangrove Partners first reported a position in ICU in Q1 2021 and held it in 2 quarters. The position peaked at $2.97M in Q2 2021. 38 funds tracked by Wall St. Rank hold ICU as of Q3 2021.

  • Mangrove Partners reported no remaining SeaStar Medical position as of Q3 2021 after selling out during the quarter.
  • Mangrove Partners sold 1,200 SeaStar Medical shares in Q3 2021, an estimated $2.97M.
  • Mangrove Partners first reported a position in SeaStar Medical in Q1 2021 and held it in 2 quarters.
  • Mangrove Partners's SeaStar Medical position peaked at $2.97M in Q2 2021.
  • 38 funds tracked by Wall St. Rank held SeaStar Medical as of Q3 2021.

Based on Mangrove Partners's 13F filing for Q3 2021, filed 15 Nov 2021.